Tailored chemo after surgery could boost pancreatic cancer survival
NCT ID NCT07044453
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving different chemotherapy drugs after pancreatic cancer surgery, based on how much tumor remains, can improve survival. About 390 patients who received chemo before surgery will be randomly assigned to one of two drug regimens. The goal is to reduce cancer recurrence and extend life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemcitabine with Nab-Paclitaxel or mFOLFIRINOX (chemotherapy drugs)
What this could lead to
If successful, this could lead to a more personalized chemotherapy plan after pancreatic cancer surgery, potentially reducing recurrence and improving survival.
What could go wrong
This is an early-phase trial (Phase 2/3) with only 390 participants, so results may not apply to all patients. Chemotherapy side effects can be severe, and the approach may not significantly improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CHU de Rouen
RECRUITINGRouen, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact